Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice

In neurodegenerative disorders, abnormally hyperphosphorylated and aggregated tau accumulates intracellularly, a mechanism which is thought to induce neuronal cell death. Methylene blue, a type of phenothiazine, has been reported to inhibit tau aggregation in vitro. However, the effect of methylene blue in vivo has remained unknown. Therefore, we examined whether methylene blue suppresses abnormal tau accumulation using P301L tau transgenic mice. At 8 to 11 months of age, these mice were orally administered methylene blue for 5 months. Subsequent results of Western blotting analysis revealed that this agent reduced detergent-insoluble phospho-tau. Methylene blue may have potential as a drug candidate for the treatment of tauopathy.

• Publication year

  2012

• Venue

  PLoS ONE

• Publication date

  2012-12-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1371/journal.pone.0052389PMID 23285020PMCID 3527507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

  2012influential reference
• Methylene Blue Reduces Aβ Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity

  2011cited by this paper
• Drugs: A tangled web of targets

  2011cited by this paper
• Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish.

  2010cited by this paper
• Methylene blue and dimebon inhibit aggregation of TDP‐43 in cellular models

  2009cited by this paper
• O3‐04–07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

  2008cited by this paper
• O1‐06–04: Methylthioninium chloride (MTC) acts as a Tau aggregation inhibitor (TAI) in a cellular model and reverses Tau pathology in transgenic mouse models of Alzheimer's disease

  2008cited by this paper
• The brain metabolic enhancer methylene blue improves discrimination learning in rats.

  2007cited by this paper
• Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes.

  2007cited by this paper
• Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization.

  2007cited by this paper
• Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins*

  2005cited by this paper
• Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria

  2004cited by this paper
• Extinction memory improvement by the metabolic enhancer methylene blue.

  2004cited by this paper
• Pharmacological evidence that methylene blue inhibits noradrenaline neuronal uptake in the rat vas deferens.

  2003cited by this paper
• Methylene blue as an antimalarial agent

  2003cited by this paper
• Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats.

  2002cited by this paper
• Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

  2000influential reference
• Stimulation of respiration by methylene blue in rat liver mitochondria

  1997cited by this paper
• Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

  1996cited by this paper
• Methylene blue administration in septic shock: a clinical trial.

  1995cited by this paper
• Concise review: methemoglobinemia.

  1993cited by this paper
• Methylene blue increases systemic vascular resistance in human septic shock

  1992cited by this paper
• A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

  1990cited by this paper
• Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich.

  1989cited by this paper
• Alzheimer‐related neuronal protein A68: Specificity and distribution

  1987cited by this paper
• The FASEB Journal • Research Communication Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways

  year unknowncited by this paper

• Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies.

  2025cites this paper
• Twenty years of therapeutic development in tauopathy mouse models: a scoping review

  2025cites this paper
• Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review

  2025cites this paper
• Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies

  2025cites this paper
• Neuronal Vulnerability of the Entorhinal Cortex to Tau Pathology in Alzheimer’s Disease

  2024cites this paper
• Hydromethylthionine rescues synaptic SNARE proteins in a mouse model of tauopathies: interference by cholinesterase inhibitors.

  2024cites this paper
• The evolution of Alzheimer’s disease therapies: A comprehensive review

  2024cites this paper
• Chaperones—A New Class of Potential Therapeutic Targets in Alzheimer’s Disease

  2024cites this paper
• Tau-targeting therapies for Alzheimer disease: current status and future directions

  2023cites this paper
• Human Tau Aggregates Are Permissive to Protein Synthesis-Dependent Memory in Drosophila Tauopathy Models

  2023cites this paper
• Implications of Tau Dysregulation in Huntington’s Disease and Potential for New Therapeutics

  2023cites this paper
• Hyperphosphorylated tau Inflicts Intracellular Stress Responses That Are Mitigated by Apomorphine

  2023cites this paper
• Hyperphosphorylated Tau Inflicts Intracellular Stress Responses that Are Mitigated by Apomorphine

  2023cites this paper
• Bringing the Spotlight to tau and TDP-43 in Frontotemporal Dementia: A Review of Promising Chemical Compounds.

  2022cites this paper
• Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease.

  2022cites this paper
• Using Caenorhabditis elegans to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions

  2022cites this paper
• Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization

  2022cites this paper
• Effects of toluidine blue O and methylene blue on growth and viability of pancreatic cancer cells

  2022cites this paper
• Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment

  2021cites this paper
• Methylene blue treatment on Alzheimer and inflammatory bowel disease

  2021cites this paper
• Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy.

  2021cites this paper
• Three‐repeat and four‐repeat tau isoforms form different oligomers

  2021cites this paper
• The Potentials of Methylene Blue as an Anti-Aging Drug

  2021cites this paper
• Upregulation of hemeoxygenase enzymes HO-1 and HO-2 following ischemia-reperfusion injury in connection with experimental cardiac arrest and cardiopulmonary resuscitation: Neuroprotective effects of methylene blue.

  2021cites this paper
• Development of a novel tau propagation mouse model endogenously expressing 3 and 4 repeat tau isoforms.

  2021cites this paper
• Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice

  2021cites this paper
• New Insights Into Drug Discovery Targeting Tau Protein

  2020cites this paper
• Pharmacological Modulators of Tau Aggregation and Spreading

  2020cites this paper
• Novel antibody against low‐n oligomers of tau protein promotes clearance of tau in cells via lysosomes

  2020cites this paper
• Asparagine residue 368 is involved in Alzheimer's disease tau strain–specific aggregation

  2020cites this paper
• Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches

  2020cites this paper
• Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation

  2020cites this paper
• Targeting Tau to Treat Clinical Features of Huntington's Disease

  2020cites this paper
• Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases

  2019cites this paper
• Azure B affects amyloid precursor protein metabolism in PS70 cells.

  2019cites this paper
• Pathogenic Tau Protein Species: Promising Therapeutic Targets for Ocular Neurodegenerative Diseases

  2019cites this paper
• [Prion-like Propagation Model of Tau].

  2019cites this paper
• Methylene Blue Ameliorates Olfactory Dysfunction and Motor Deficits in a Chronic MPTP/Probenecid Mouse Model of Parkinson's Disease.

  2018cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• Azure C Targets and Modulates Toxic Tau Oligomers.

  2018cites this paper
• Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease.

  2018cites this paper
• Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots

  2017cites this paper
• Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer’s disease model mice

  2017cites this paper
• From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue

  2017cites this paper
• Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.

  2017cites this paper
• Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening

  2017cites this paper
• A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy

  2017cites this paper
• The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity

  2017cites this paper
• Tau-Centric Therapies for Treating Alzheimer’s Disease

  2017cites this paper
• The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons.

  2017cites this paper
• Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

  2017cites this paper
• The Abundance of Nonphosphorylated Tau in Mouse and Human Tauopathy Brains Revealed by the Use of Phos-Tag Method.

  2016cites this paper
• Targets and Strategies Toward the Development of Alzheimer Therapeutics

  2016cites this paper
• Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease

  2016cites this paper
• Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?

  2016cites this paper
• Intrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation

  2016cites this paper
• Therapeutic Approaches Targeting Pathological Tau Aggregates.

  2016cites this paper
• Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease

  2016cites this paper
• The role of hypertension and inflammation on the cognitive symptoms of Alzheimer's disease patients

  2016cites this paper
• Prospects and Challenges for Alzheimer Therapeutics

  2016cites this paper
• Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease.

  2016cites this paper
• Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease

  2016cites this paper
• The role of tau in Alzheimer’s Disease: Effects of Lys-280 and Lys-281 acetylation on tau function and structure

  2016cites this paper
• Caloric restriction and the precision-control of autophagy: A strategy for delaying neurodegenerative disease progression.

  2016cites this paper
• Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

  2016cites this paper
• Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases.

  2016cites this paper
• Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.

  2016cites this paper
• Inhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules.

  2016cites this paper
• Fonctions atypiques de la protéine Tau : rôles dans la protection des acides nucléiques et le métabolisme des ARN

  2016cites this paper
• Update on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease

  2015cites this paper
• Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models

  2015cites this paper
• Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies

  2015cites this paper
• Rapamycin Ester Analog CCI-779/Temsirolimus Alleviates Tau Pathology and Improves Motor Deficit in Mutant Tau Transgenic Mice

  2015cites this paper
• Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo.

  2015cites this paper
• Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies

  2015cites this paper
• PE859, a Novel Tau Aggregation Inhibitor, Reduces Aggregated Tau and Prevents Onset and Progression of Neural Dysfunction In Vivo

  2015cites this paper
• Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau

  2015cites this paper
• Methylene Blue Inhibits Caspases by Oxidation of the Catalytic Cysteine

  2015cites this paper
• Targeting Assembly and Disassembly of Protein Aggregates

  2015cites this paper
• Swa2, the yeast homolog of mammalian auxilin, is specifically required for the propagation of the prion variant [URE 3‐1]

  2015cites this paper
• Antisense Reduction of the Protein Tau Attenuates Neuronal Hyperexcitability and Permits Clearance of Intraneuronal Tau Accumulations in vivo

  2014cites this paper
• The tau of PSP: A long road to treatment

  2014cites this paper
• Strategizing the Development of Alzheimer’s Therapeutics

  2014cites this paper
• Specific Calpain Inhibition by Calpastatin Prevents Tauopathy and Neurodegeneration and Restores Normal Lifespan in Tau P301L Mice

  2014influential citation
• Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

  2014cites this paper
• Methylene Blue Modulates β-Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice*

  2014cites this paper
• Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.

  2014cites this paper
• Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures.

  2014cites this paper
• Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice

  2013cites this paper
• The Role of Molecular Chaperones in the Etiology and Treatment of Psychiatric Diseases in the Elderly

  2013cites this paper
• Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies.

  2013cites this paper
• Tau pathology and neurodegeneration.

  2013cites this paper
• Validation of Tau aggregation model in HEK cells and cortical rat neurons

  2013cites this paper